Novel gene-expression profiling technology
SkylineDx has been awarded a multi-million euro Horizon 2020 grant from the European Commission to develop a new, and novel gene-expression profiling technology, which is intended to predict the most effective treatment strategy for patients with multiple myeloma (MM).
The consortium of European partners includes Erasmus MC (EMC, Rotterdam), Myeloma Patients Europe (MPE, Brussels), University of Turin (Unito, Turin) and the Institute for Medical Technology Assessment (iMTA, Rotterdam).
Improve survival and quality of life
“SkylineDx appreciates all of the support of our partners and is looking forward to expanding the portfolio to help physicians personalize treatment options for those who receive a diagnosis of multiple myeloma,” said Dharminder S. Chahal, Chief Executive Officer of SkylineDx. “Helping healthcare professionals make precision medicine treatment decisions for their patients has always been the forefront of SkylineDx’s mission and we believe that this test will give patients the chance to improve their survival and quality of life.”
“We need to incorporate tools like the MMprofiler in order to best identify those patients who may benefit from a more aggressive treatment regime versus those who may benefit from a less aggressive treatment” said Andrzej Jakubowiak, MD, PhD, professor of medicine and director of the University of Chicago’s myeloma program. “Tools like the MMprofiler are absolutely important to help us not to lose sight of what’s best for our patients.”
Read more about SkylineDx
Awarded Grant: Horizon2020